Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, cut the risk of melanoma recurrence and death by 42 percent compared to Keytruda alone in a Phase 3 trial. Six melanoma specialists described the findings as a clinically meaningful result for patients who underwent surgery. The investigational treatment uses a patient's own tumor to create a bespoke neoantigen therapy. While experts view the results as a major advancement, further research and reviews are required before the therapy achieves widespread clinical availability.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Moderna and Merck's personalized mRNA cancer vaccine cut the risk of cancer recurrence and death by 42 percent compared with standard treatment in a trial.
- ✓ Six melanoma specialists stated the vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.
- ✓ The INTerpath-001 trial shows the vaccine reduces melanoma recurrence by 42 percent compared to Keytruda alone.
What changed
Moderna and Merck released top-line Phase 3 trial data showing the vaccine reduced death and recurrence by 42 percent.
Live updates
-
Moderna and Merck Cancer Vaccine Cuts Melanoma Risk by 42 Percent
Moderna and Merck announced that their personalized mRNA cancer vaccine, intismeran autogene, cut the risk of melanoma recurrence and death by 42 percent compared to Keytruda alone in a Phase 3 trial. Six melanoma specialists described the findings as a clinically meaningful result for patients who underwent surgery. The investigational treatment uses a patient's own tumor to create a bespoke neoantigen therapy. While experts view the results as a major advancement, further research and reviews are required before the therapy achieves widespread clinical availability.
Why it matters
The positive data arrive after a century of failed attempts to build effective cancer vaccines. The current trial, known as INTerpath-001, represents the first successful Phase 3 trial for a personalized neoantigen mRNA therapy. The treatment is administered after surgery alongside pembrolizumab, also known as Keytruda, to prevent melanoma from returning.
What is confirmed
- Moderna and Merck's personalized mRNA cancer vaccine cut the risk of cancer recurrence and death by 42 percent compared with standard treatment in a trial.
- Six melanoma specialists stated the vaccine results represent a clinically meaningful result for melanoma patients who underwent surgery.
- The INTerpath-001 trial shows the vaccine reduces melanoma recurrence by 42 percent compared to Keytruda alone.
Still unconfirmed
- Scientists need to determine how widely the approach can work across other cancer types following the melanoma study.
What to watch next
- Further research and regulatory reviews to determine if the vaccine can become widely available.
- Broader applications of the mRNA technology to other cancer types beyond melanoma.
confidence 100%Sources used for this update (9)
- arstechnica.com — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- www.scientificamerican.com — Here’s what Moderna’s latest mRNA cancer vaccine data actually show
- www.cnbc.com — Moderna, Merck's cancer vaccine data a major advancement - CNBC
- www.statnews.com — What's next for cancer vaccines after successful melanoma study
- www.nbcnews.com — Personalized mRNA vaccine for melanoma cut risk of cancer’s ...
- www.sciencealert.com — World-First Cancer Vaccine Cuts Melanoma Recurrence or Death ...
- www.bioreview.com — Merck Moderna Phase 3 Win: Personalized mRNA Cancer Vaccine ...
- theprint.in — Cancer vaccines move a step forward. Moderna-Merck trial ...
- www.uchealth.org — Personalized mRNA melanoma vaccine with Keytruda shows ...
-
Moderna and Merck Prepare for ESMO Data Reveal on mRNA Vaccine
Moderna and Merck are preparing for a major data reveal at the ESMO 2026 conference regarding their personalized mRNA cancer vaccine, intismeran autogene. Also known as mRNA-4157 or V940, the investigational therapeutic is built from a patient's own tumor and administered after surgery alongside pembrolizumab, or Keytruda, to prevent melanoma from returning. This marks the world's first successful personalized neoantigen mRNA therapy to pass a large Phase 3 trial. Independent analysts and biotech reporters are closely watching the upcoming presentation for detailed insights into the trial results, building on earlier development strategies outlined by corporate executives.
Why it matters
The therapy represents a potential turning point in oncology by combining individualized neoantigen treatments with established immunotherapies like Keytruda. While prior trial data established the vaccine's success in melanoma, clinicians and investigators are analyzing how the approach performs across multiple tumor types. Upcoming scientific presentations will provide critical metrics on efficacy and patient outcomes as the companies advance toward regulatory filings.
What is confirmed
- Intismeran autogene, also referred to as mRNA-4157 or V940, is an investigational individualized neoantigen therapy built from each patient's own tumor.
- The therapy is given after surgery alongside the anti-PD-1 antibody pembrolizumab, known as Keytruda, to reduce the risk of melanoma returning.
Still unconfirmed
- The upcoming ESMO 2026 presentation will reveal expanded survival metrics or cost projections for intismeran autogene.
What to watch next
- The ESMO 2026 data reveal by senior biotech reporter Adam Feuerstein and company presentations.
- Regulatory filing updates from Moderna and Merck regarding tumor types beyond melanoma.
confidence 100%Sources used for this update (3)
- www.statnews.com — What to expect from the Moderna-Merck cancer vaccine data reveal
- cancer.aestheticsadvisor.com — Moderna and Merck’s Personalized mRNA Cancer Vaccine: Phase 3 ...
- slashhealth.com — mRNA Cancer Vaccine: First Phase 3 Success Explained
-
Moderna and Merck Detail Strategy for mRNA Cancer Vaccine
Moderna and Merck executives Stephen Hoge and Dean Li outlined their development strategy at the STAT Summit in Boston, detailing plans to pair personalized mRNA vaccines with Keytruda to target tumors. The companies are preparing regulatory filings and exploring applications across multiple tumor types following positive Phase 3 melanoma data. The therapy, intismeran autogene, represents the world's first successful personalized neoantigen mRNA therapy to pass a large Phase 3 trial. However, experts continue to scrutinize the treatment regarding manufacturing costs, safety, and whether it extends overall patient survival.
Why it matters
The collaboration builds on Merck's previous $250 million investment in the therapy and marks a potential turning point in oncology. Analysts and clinicians are gathering at the European Society of Medical Oncology meeting in Madrid to examine detailed data for the vaccine. While the results offer real hope for melanoma patients, widespread adoption hinges on navigating complex regulatory hurdles and healthcare system affordability.
What is confirmed
- Moderna and Merck executives Stephen Hoge and Dean Li detailed their strategy for pairing Keytruda with personalized mRNA vaccines at the STAT Summit in Boston.
- The personalized mRNA therapy, known as intismeran autogene or mRNA-4157/V940, significantly reduces the risk of melanoma returning after surgery.
- Intismeran autogene is the world's first successful personalized mRNA neoantigen therapy to pass a large Phase 3 trial.
- Merck and Moderna are preparing regulatory filings and exploring applications across multiple tumor types.
Still unconfirmed
- Unanswered questions remain regarding whether the experimental vaccine actually extends patients' lives and whether healthcare systems can afford it.
What to watch next
- Detailed data presentations at the ESMO 2026 meeting in Madrid
- Upcoming regulatory filings by Moderna and Merck
confidence 100%Sources used for this update (8)
- www.curetoday.com — What Is a Personalized Cancer Vaccine? What Patients Should ...
- www.statnews.com — Moderna, Merck detail strategy for mRNA cancer vaccine and ...
- www.meetlifesciences.com — The latest breakthrough in personalized cancer vaccines
- www.smartcancer.org — Moderna Merck Cancer Vaccine Phase 3 Results 2026: Intismeran ...
- evagene.com — Moderna and Merck outline strategy for pairing personalised ...
- rocketnews.com — Merck and Moderna have ‘lot of exploring to do’ after initial ...
- www.trialsitenews.com — Moderna’s mRNA Cancer Vaccine: A Genuine Breakthrough or an ...
- www.biospace.com — Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
-
Moderna-Merck's mRNA Cancer Vaccine Shows Promise
Moderna and Merck's personalized mRNA cancer vaccine, intismeran autogene, has yielded positive Phase 3 melanoma data, supporting the potential for individualized cancer treatment. This development builds on Merck's previous $250 million investment in the therapy. The vaccine's success could pave the way for a 'personalized medicine revolution' in oncology. However, challenges in manufacturing, diagnostics, regulation, and reimbursement may hinder widespread adoption.
Why it matters
The collaboration between Moderna and Merck leverages two decades of research in customized therapies designed to train the immune system to target specific patient tumors. The treatment's progress is being closely watched by industry researchers, who are examining divergent clinical trial results and addressing complex questions surrounding mRNA cancer treatments. The approach has generated substantial scientific excitement, with some experts seeing it as a potential game-changer in cancer treatment.
What is confirmed
- Moderna and Merck's individualized neoantigen therapy intismeran autogene has put personalized mRNA cancer treatment on the path to market.
- Merck exercised an option on the personalized RNA-based cancer vaccine, involving a $250 million payment.
- The U.S. government is launching a cancer vaccine initiative modeled on Operation Warp Speed, with $200 million in funding.
Still unconfirmed
- The cancer vaccine initiative may not be able to change the game with 70x less funding than its pandemic predecessor.
What to watch next
- Merck's Q3 earnings report for updates on their data blitz
- The launch execution of RevMed's pancreatic cancer treatment
- The progress of the U.S. government's cancer vaccine initiative
confidence 85%Sources used for this update (3)
- insights.citeline.com — Moderna-Merck’s Intismeran Exposes The Personalized Medicine ...
- www.biospace.com — Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
- biotechmorning.com — The Government Wants to Warp Speed Its Way to a Cancer Vaccine
-
Moderna and Merck Score Phase 3 Success with mRNA Cancer Vaccine
Moderna and Merck have reported positive Phase 3 melanoma data for their individualized mRNA cancer therapy, drawing fresh industry attention to oncology pipelines. This milestone follows Merck's previous exercise of an option on the personalized RNA-based cancer vaccine, which involved a $250 million payment. The treatment leverages two decades of development aimed at custom-made therapies designed to train the immune system to target specific patient tumors. While the overall approach generates substantial scientific excitement, researchers across the field continue to examine divergent clinical trial results and address complex questions surrounding mRNA cancer treatments.
Why it matters
The collaboration between Moderna and Merck represents a major financial and developmental commitment to customized oncology treatments. Developing these custom-made therapies has taken two decades of scientific research to reach late-stage clinical evaluation. Researchers are closely monitoring the broader implications of these trials as the field navigates divergent outcomes across different studies.
What is confirmed
- Moderna and Merck reported positive Phase 3 melanoma data for their individualized mRNA cancer therapy.
What to watch next
- Broader clinical trial results for mRNA cancer therapies across the oncology field
- Further commercial and developmental milestones from the Moderna and Merck partnership
confidence 100%Sources used for this update (2)
- marketchameleon.com — Moderna’s individualized mRNA cancer therapy hits a Phase 3...
- pharmastockstoday.com — Moderna and Merck Cancer Vaccine Trial Success Puts MRNA and ...
-
Merck Invests $250M in Moderna Cancer Vaccine
Merck & Co has exercised an option on a personalized RNA-based cancer vaccine developed by Moderna, transferring a payment of $250 million. This milestone follows two decades of development for custom-made treatments that train the immune system to target individual patient tumors. Meanwhile, researchers across the field are examining divergent clinical trial results and grappling with difficult questions surrounding mRNA cancer vaccines, even as the overall approach continues to generate significant scientific excitement.
Why it matters
The collaboration between Moderna and Merck began in 2016 and expanded two years later to incorporate additional candidates. mRNA therapeutics previously shifted focus toward infectious diseases during the COVID-19 pandemic before returning to oncology applications.
What is confirmed
- Merck & Co took up an option on a personalized RNA-based cancer vaccine with a payment of $250 million.
- The collaboration between Merck and mRNA vaccine specialist Moderna was first agreed in 2016.
- The partnership was expanded two years after its inception to include additional candidates.
Still unconfirmed
- Divergent trial results on cancer vaccines have the field grappling with hard questions.
What to watch next
- Further clinical trial data releases for mRNA cancer vaccines
- Additional option exercises or expansions in the Moderna and Merck partnership
confidence 100%Sources used for this update (5)
- pharmaphorum.com — Merck gets on board with Moderna cancer vaccine in $250m deal
- products.modernatx.com — Find vaccines by Moderna near you
- products.modernatx.com — mNEXSPIKE® (COVID-19 Vaccine, mRNA) by Moderna
- labels.modernatx.com — Moderna
- www.statnews.com — Divergent trial results on cancer vaccines have field grappling with hard questions
-
Moderna and Merck Cancer Vaccine Sparks Personalized Medicine Era
Cancer experts are hailing the success of Moderna and Merck's personalized melanoma vaccine as the start of an era of custom-made treatments that train the immune system to fight an individual patient tumor. Following two decades as an unfulfilled scientific concept, the Phase 3 trial results demonstrated a 49 percent reduction in disease progression or death, marking a major milestone for mRNA therapeutics following its pivot from infectious diseases during the COVID-19 pandemic.
Why it matters
The recent Phase 3 trial data presented at the European Society for Medical Oncology Congress 2026 builds on five-year results showing a significant reduction in skin cancer returning or spreading after surgery when combined with Keytruda. A 2026 analysis indicates that cancer represents the vast majority of non-communicable disease candidates in the mRNA pipeline, with over one hundred cancer-focused candidates currently in development across dozens of companies and research institutes.
What is confirmed
- The personalized cancer vaccine cut melanoma recurrence by 49 percent in Phase 3.
- A 2026 analysis published in Human Vaccines and Immunotherapeutics identified 121 non-communicable disease candidates, including 102 cancer-focused candidates.
- The development pipeline involves 85 developers, comprising 50 companies and 35 institutes and hospitals.
Still unconfirmed
- Researchers, a founder, and an investor are examining what changed regarding costs and which tumors will be targeted next.
What to watch next
- Phase 3 trial data for subsequent tumor applications beyond melanoma
- Additional clarity on treatment costs and future pricing models
confidence 100%Sources used for this update (4)
- madison.com — Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
- www.biospectrumasia.com — mRNA’s Cancer BreakthroughmRNA’s Cancer Breakthrough
- pharmaphorum.com — Data builds behind Moderna's skin cancer vaccine
- www.venturesaccelerated.com — Cancer Vaccines, no longer science fiction - Ventures Accelerated
-
Moderna and Merck Advance Personalized mRNA Cancer Vaccine Data
Moderna and Merck presented full Phase 3 trial data for their personalized mRNA melanoma vaccine, intismeran autogene, combined with Keytruda at the European Society for Medical Oncology Congress 2026. The late-stage study involving more than 1,100 patients met its primary endpoint, showing the customized regimen significantly reduces the risk of skin cancer returning or spreading after surgery compared to Keytruda alone. While the milestone drove a 29.1 percent jump in Moderna stock and sparked hopes for broader tumor applications, unresolved questions remain regarding treatment durability, biomarkers, and delivery challenges.
Why it matters
Traditional chemotherapy destroys both healthy and cancerous cells, while standard immunotherapy broadly stimulates the immune system. In contrast, personalized mRNA cancer vaccines are designed to train the immune system to target specific tumors based on individual genetic profiles. Moderna is also pursuing investment and manufacturing cooperation with Middle East partners as its pipeline visibility grows.
What is confirmed
- The Phase 3 INTerpath-001 trial evaluated personalized cancer vaccine intismeran autogene plus Keytruda in melanoma.
- Full trial data was presented earlier this month at the European Society for Medical Oncology Congress 2026.
- The Phase 3 study involved more than 1,100 patients.
- Moderna shares rose 29.1 percent following the melanoma vaccine success.
Still unconfirmed
- Doctors hope the personalized vaccine approach will work against many types of tumors beyond melanoma.
- Moderna is holding talks with Middle East partners about potential investment and manufacturing cooperation.
What to watch next
- Resolution of ongoing questions regarding durability, biomarkers, and delivery for individualized vaccines.
- Further updates on potential investment and manufacturing cooperation between Moderna and Middle East partners.
confidence 100%Sources used for this update (4)
- finance.yahoo.com — Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success ...
- www.medscape.com — Personalized Cancer Vaccines: What Challenges Remain? - Medscape
- cde.news — Moderna, Merck breakthrough could usher in wave of cancer ...
- londondaily.com — Moderna and Merck's Personalized Cancer Vaccine Succeeds in ...
-
Moderna-Merck Melanoma Vaccine Succeeds in Late-Stage Trial
A personalized mRNA cancer vaccine developed by Moderna and Merck, combined with the immunotherapy drug Keytruda, succeeded in a late-stage clinical trial for the deadly skin cancer melanoma. Makers reported that the combination regimen significantly extended the time patients lived without their melanoma returning, compared to using Keytruda alone. This development potentially opens a new method for treating the disease. Moderna specializes in RNA therapeutics and mRNA vaccines, which use messenger RNA molecules to carry protein instructions that trigger targeted immune responses.
Why it matters
Moderna bases its operations in Cambridge, Massachusetts, deriving its name from modified RNA and modern concepts. The company previously developed the Spikevax COVID-19 vaccine in collaboration with the United States National Institute of Allergy and Infectious Diseases and the Biomedical Advanced Research and Development Authority. Another version of their COVID-19 vaccine, known as Mnexspike or mRNA-1283, gained approval for medical use in the United States in May 2025 and in the European Union in February 2026.
What is confirmed
- A personalized mRNA cancer vaccine combined with Keytruda succeeded in a late-stage trial for melanoma.
- The combination regimen significantly extended the time patients lived without their melanoma returning compared to Keytruda alone.
- Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics and mRNA vaccines.
What to watch next
- Release of specific Phase 3 clinical trial data to the public.
- Presentations at upcoming oncology congresses regarding the melanoma vaccine.
confidence 100%Sources used for this update (9)
- www.modernatx.com — Pioneering mRNA technology - Moderna
- en.wikipedia.org — Moderna - Wikipedia
- www.modernatx.com — Company Culture - Moderna
- finance.yahoo.com — Moderna, Inc. (MRNA) Stock Price, News, Quote & History - Yahoo...
- www.cnn.com — Moderna and Merck say melanoma vaccine succeeded in large trial
- www.cnbc.com — Moderna, Merck cancer vaccine shows initial late-stage melanoma...
- en.wikipedia.org — Moderna COVID-19 vaccine - Wikipedia
- investors.modernatx.com — Investor Relations - Moderna
- www.fda.gov — Moderna COVID-19 Vaccine | FDA
-
Moderna shares rise on oncology symposium slot as stock hits yearly high
Moderna shares rose 9% after the company secured a Presidential Symposium slot at Europe's leading oncology congress to present Phase 3 melanoma data. This surge contributes to a yearly stock increase of roughly 510%, with prices climbing from about $25 to about $173 by September 21, 2026. While the market reacts to the prestige of the presentation slot, the specific Phase 3 dataset has not been released to the public. This performance significantly outpaces the S&P 500 and Pfizer over the same period.
Why it matters
The market volatility stems from the partnership between Moderna and Merck to develop a personalized mRNA cancer vaccine. The intismeran autogene trial targets melanoma. Investors are using scheduling milestones as proxies for the trial's success.
What is confirmed
- Moderna stock rose roughly 510% over the year to September 21, 2026, moving from about $25 to about $173.
- The S&P 500 gained 18.5% with dividends reinvested over the same window as Moderna's yearly run.
- Pfizer stock rose about 23% over the same period.
Still unconfirmed
- Moderna shares rose 9% because the company secured a Presidential Symposium slot at Europe's top oncology congress.
- The Phase 3 melanoma data remains unseen.
What to watch next
- Release of the actual Phase 3 melanoma dataset
- The official presentation at the oncology congress
confidence 90%Sources used for this update (2)
- 247wallst.com — Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
- finance.yahoo.com — Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
-
Moderna Stock Climbs Amid Ongoing Cancer Vaccine Gains
Moderna shares climbed 6 percent, extending a 137 percent monthly surge driven by optimism surrounding its late-stage cancer vaccine trial results with Merck. Stock prices for Moderna rose by 9.37 percent as market enthusiasm continued for the personalized treatment. This sustained financial momentum builds on the success of the intismeran autogene Phase 3 melanoma trial. The strong market performance positions Moderna alongside competitors like BioNTech and Novavax, which also edged higher during the trading session.
Why it matters
The recent market surge reflects investor confidence following the success of the intismeran autogene Phase 3 melanoma trial conducted by Moderna and Merck. President Stephen Hoge previously noted that these results support broader initiatives to apply T-cell priming across various tumor types. The commercialization phase now presents hurdles as five other drugmakers pursue similar personalized therapies.
What is confirmed
- Moderna shares climbed 6 percent, extending a 137 percent monthly surge.
- Moderna Inc. stocks traded up by 9.37 percent following late-stage vaccine trial results.
Still unconfirmed
- The market surge is driven by a bet revealed in a quiet peer stock.
What to watch next
- Further commercialization updates from Moderna and Merck regarding intismeran autogene
- Market performance of competitor drugmakers pursuing personalized cancer therapies
confidence 90%Sources used for this update (3)
- jen.jiji.com — Nadal returns to the court: the surprise announcement and the match date - Video
- 247wallst.com — Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
- www.timothysykes.com — MRNA Stock Rockets As Cancer Breakthrough Redefines The Story
-
Moderna and Merck's Melanoma Vaccine Clears Phase 3 Trial
The personalized cancer vaccine intismeran autogene met its primary endpoint in a Phase 3 melanoma trial conducted by Moderna and Merck. President Stephen Hoge stated these results support a larger initiative to apply T-cell priming across various tumor types. While the clinical phase is complete, the companies now face commercialization challenges. This success has positioned the pair as leaders in a competitive field where five other drugmakers are now pursuing similar personalized therapies.
Why it matters
Personalized vaccines use genetic instructions to prime the immune system against specific tumor markers. This approach differs from traditional treatments by tailoring the medicine to the individual patient's cancer. The shift toward this model depends on whether these clinical wins can be scaled for mass production.
What is confirmed
- The Phase 3 melanoma trial of intismeran autogene met its primary endpoint.
- Moderna President Stephen Hoge stated positive results support using T-cell priming in multiple tumor types.
Still unconfirmed
- Five other drugmakers are chasing Merck and Moderna with similar personalized cancer vaccines.
What to watch next
- Commercial launch details and market access strategies
- Clinical trial results for other tumor types using T-cell priming
confidence 90%Sources used for this update (3)
- www.biospace.com — 5 drugmakers chasing Merck and Moderna in the cancer vaccine race
- finance.yahoo.com — Moderna’s Cancer Vaccine Win Fuels Broad Push Across Tumor Types
- www.pymnts.com — Moderna’s AI-Built Cancer Vaccine Clears Phase 3 With Merck
-
Moderna and Merck mRNA Vaccine Improves Melanoma Survival
A combined treatment of a new mRNA cancer vaccine and Keytruda has sharply improved survival rates for melanoma patients. Trial results indicate the vaccine can slow cancer growth. While the success suggests a shift toward personalized medicine, the full data from the Moderna and Merck trial have not yet been presented. The transition to market remains hindered by significant barriers. This development marks a shift in how clinicians approach skin cancer treatment by combining immunotherapy with personalized genetic instructions.
Why it matters
Personalized mRNA vaccines are designed to target specific mutations in a patient's tumor. This approach differs from traditional vaccines by treating existing disease rather than preventing infection. The partnership between Moderna and Merck leverages mRNA technology alongside established checkpoint inhibitors.
What is confirmed
- A new mRNA cancer vaccine used with Keytruda improves melanoma survival.
- A melanoma vaccine trial demonstrates the ability to slow cancer growth.
Still unconfirmed
- mRNA cancer vaccines face significant barriers to market.
What to watch next
- The presentation of full trial data from Moderna and Merck
- Regulatory filings for the mRNA melanoma vaccine
- Identification of specific market barriers hindering vaccine distribution
confidence 70%Sources used for this update (5)
- Fierce Biotech — Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?
- UCHealth — Clinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survival
- BioPharma Dive — mRNA cancer vaccines’ biggest barriers to market
- KING5.com — A vaccine trial for melanoma shows it can slow down cancer growth: HealthLink
- cancerletter.com — The data from Moderna and Merck’s trial have yet to be presented
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community